IS5100A - Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L - Google Patents

Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L

Info

Publication number
IS5100A
IS5100A IS5100A IS5100A IS5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A
Authority
IS
Iceland
Prior art keywords
treatment
lupus nephritis
cd40l antibodies
cd40l
antibodies
Prior art date
Application number
IS5100A
Other languages
English (en)
Icelandic (is)
Inventor
L. Kalled Susan
W. Thomas David
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5100A publication Critical patent/IS5100A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IS5100A 1997-01-10 1999-06-30 Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L IS5100A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (1)

Publication Number Publication Date
IS5100A true IS5100A (is) 1999-06-30

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5100A IS5100A (is) 1997-01-10 1999-06-30 Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L

Country Status (19)

Country Link
US (2) US20030031668A1 (enExample)
EP (2) EP1357131A3 (enExample)
JP (1) JP2001508441A (enExample)
KR (2) KR20000070034A (enExample)
CN (2) CN1572325A (enExample)
AU (1) AU5709798A (enExample)
BR (1) BR9714523A (enExample)
CA (1) CA2277222A1 (enExample)
CZ (1) CZ297680B6 (enExample)
EA (2) EA006314B1 (enExample)
EE (1) EE9900273A (enExample)
HU (1) HUP0000833A3 (enExample)
IL (1) IL130784A0 (enExample)
IS (1) IS5100A (enExample)
NO (1) NO993274L (enExample)
NZ (1) NZ337072A (enExample)
PL (1) PL190663B1 (enExample)
TR (7) TR200001251T2 (enExample)
WO (1) WO1998030240A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
KR20010072564A (ko) * 1998-04-03 2001-07-31 존 에프. 카바나프 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
WO2000036103A1 (en) 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
EP3718564B1 (en) 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
US8435514B2 (en) 2008-12-05 2013-05-07 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
IL244149B2 (en) 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
JP2018526443A (ja) * 2015-08-31 2018-09-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
EP0874637A1 (en) * 1996-01-16 1998-11-04 The Trustees of Columbia University in the City of New York Therapeutic applications of t-bam (cd40l) technology to treat inflammatory kidney diseases
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
HUP0000833A3 (en) 2001-09-28
EP1357131A3 (en) 2004-02-11
CN1572325A (zh) 2005-02-02
TR200001251T2 (tr) 2000-09-21
TR199902191T2 (xx) 1999-12-21
BR9714523A (pt) 2000-05-02
CA2277222A1 (en) 1998-07-16
HUP0000833A2 (en) 2000-07-28
NO993274L (no) 1999-09-10
KR20000070034A (ko) 2000-11-25
EA006314B1 (ru) 2005-10-27
EP1357131A2 (en) 2003-10-29
PL334495A1 (en) 2000-02-28
TR200001246T2 (tr) 2000-07-21
PL190663B1 (pl) 2005-12-30
AU5709798A (en) 1998-08-03
CZ244499A3 (cs) 1999-10-13
CZ297680B6 (cs) 2007-03-07
JP2001508441A (ja) 2001-06-26
EA199900636A1 (ru) 2000-02-28
TR200001249T2 (tr) 2000-11-21
KR20050089165A (ko) 2005-09-07
NZ337072A (en) 2000-12-22
KR100618081B1 (ko) 2006-08-30
TR200001248T2 (tr) 2000-07-21
WO1998030240A1 (en) 1998-07-16
EE9900273A (et) 2000-02-15
EA200501076A1 (ru) 2006-06-30
EP0948355A1 (en) 1999-10-13
US20070190053A1 (en) 2007-08-16
IL130784A0 (en) 2001-01-28
TR200001250T2 (tr) 2001-03-21
NO993274D0 (no) 1999-07-01
CN1247472A (zh) 2000-03-15
US20030031668A1 (en) 2003-02-13
TR200001247T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
IS5100A (is) Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
EP1126838A4 (en) NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
DE69840349D1 (de) Omatischem herunterladen
ZA99161B (en) Ó-ketoamide inhibitors of 20S proteasome.
EE200000283A (et) Keemilised ühendid
EE200000284A (et) Keemilised ühendid
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
ID24323A (id) Proses hidrosianasi yang tertingkatkan
DK1077940T3 (da) 4-Phenylpiperidiner til behandling af pruritiske dermatoser
DE19882742T1 (de) Hahnhalteteil
DE69840142D1 (de) Kathodenbogen-Beschichtungsgerät
DE59806422D1 (de) Partikelfreies gaserzeugendes Gemisch
DK0923978T3 (da) Fremgangsmåde til behandling af röggas
DK0930091T3 (da) Fremgangsmåde til behandling af röggasser
DK0817760T3 (da) Fremgangsmåde til stabillisering af slam
EP1212075A4 (en) PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF MEMBERS OF THE CD66 FAMILY (CEACAM)
ID22572A (id) Proses yang disempurnakan untuk pembuatan 3,5,5-trimetilsikloheksa-3-en-1-on (betha-isoforon) dengan isomerisasi 3,5,5-trimetilsikloheksa-2-en-1-on (alpha-isoforon) (ii)
DK1042228T3 (da) Fremgangsmåde til behandling af cementslam
ID25893A (id) Proses pelletisasi
ID20679A (id) Proses untuk memperkaya bijih-bijih oksida yang mengandung-nikel
ATE216355T1 (de) Klärschlammvererdung
DE69835190D1 (de) Schaltung zur Taktrückgewinnung
DK0862939T3 (da) Fremgangsmåde til behandling af röggas
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi